An Open Label Balanced Randomized Single Dose Two Treatment Two Sequence Two Period Two Way Crossover Oral Bioequivalence Study Comparing Resmetirom 100 mg Tablets Manufactured by Mankind Pharma Limited India With Rezdiffra Resmetirom 100 mg Tablets Distributed by Madrigal Pharmaceuticals United States of America In Healthy Human Subjects Under Fasting Condition - NIL

Start Date21 Apr 2025

Sponsor / Collaborator

Mankind Pharma Ltd.

NCT06397872

/ Enrolling by invitationPhase 1

A Phase 1, Multi-center, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function

The purpose of this study is to directly characterize the pharmacokinetic (PK) profiles of resmetirom and its major metabolite (MGL-3623) following oral administration of 100 mg resmetirom (QD x 6 days) in subjects with severe renal impairment (RI) compared to healthy matched control subjects with normal renal function.

Start Date05 Mar 2024

Sponsor / Collaborator

Madrigal Pharmaceuticals, Inc.

NCT05500222

/ Active, not recruitingPhase 3

A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on Liver-related Outcomes in Patients With Well-compensated (Child-Pugh A) Non-alcoholic Steatohepatitis (NASH) Cirrhosis (MAESTRO-NASH-OUTCOMES)

This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical Outcome event.

Start Date26 Aug 2022

Sponsor / Collaborator

Madrigal Pharmaceuticals, Inc.

100 Clinical Results associated with Resmetirom

100 Translational Medicine associated with Resmetirom

100 Patents (Medical) associated with Resmetirom

221

Literatures (Medical) associated with Resmetirom

01 Sep 2025·BONE

Metabolic, skeletal, and cartilage effects of a high-fat diet and the therapeutic impact of MGL3196 are age- and sex-dependent in mice

Article

Author: Sechriest, V F ; Muralidharan, A ; Mohan, S ; Gomez, G A ; Quincey, A ; Perez, O ; Pourteymoor, S ; Edderkaoui, B ; Kesavan, C

Aged individuals with type 2 diabetes (T2D) may suffer from complications of common comorbid conditions like osteoporosis or osteoarthritis. MGL3196 (MGL) is a therapeutic thyroid hormone receptor beta (TRβ) agonist that has been shown to rescue non-alcoholic steatohepatitis by enhancing lipid metabolism. In a previous study, we demonstrated that MGL treatment protected against high-fat diet (HFD)-induced adiposity but increased HFD-induced trabecular bone loss in male mice. In this study, we explored the impact of MGL treatment on adiposity, bone, and cartilage in aged-21-month-old C57BL/6J mice after a 12-week HFD regimen. Our results show that MGL reduced body weight as well as adverse effects caused by HFD adiposity, in male mice only. Aged HFD-fed male mice experienced cortical bone loss, in contrast to the trabecular bone loss observed in adult male mice. Notably, MGL treatment further exacerbated the cortical bone loss. Mechanical testing of tibias from aged male mice by 3-point bending revealed a reduced maximum load and tibia stiffness with HFD and MGL treatment. Transcriptome analyses for cortical bone formation regulators unveiled a decreased expression of Wnt16 and increased expression of the Wnt inhibitor, Sost, in the bones of HFD-fed male mice. Additionally, measurements of articular cartilage indicated that MGL treatment reduced articular cartilage degradation in both sexes, which was attributed to aging and a HFD. Our findings suggest tailored therapies are necessary to address the adverse effects of a HFD on fat, bone, and cartilage metabolism, specifically considering factors such as age and sex.

01 Aug 2025·MEDICINA CLINICA

Review

Author: Arab, Juan Pablo ; Romero-Gómez, Manuel ; Ferretti, Sebastián

The proposal for a nomenclature changes stems from the inaccuracy of the original term, as well as on the absence of any allusion to metabolic disorders and the stigma generated by the use of the terms "nonalcoholic" and "fatty". The term thus proposed a change from basing its definition on the existence of a histological lesion typical of alcohol damage in the absence of significant alcohol consumption to being defined by the presence of hepatic steatosis demonstrated through biopsy or imaging methods associated with cardiometabolic risk factors, such as diabetes, obesity, arterial hypertension or dyslipidemia in the absence of pathological alcohol consumption. This change has made it possible to define hepatic steatosis as a disease attributed to metabolic disorder and alcohol. This proves the specific similarities and differences between metabolic hepatic steatosis and alcoholic hepatic steatosis, both in their pathogenesis and in the role of genetics and the intestine-liver axis, as well as in potential therapeutic options such as resmetirom or semaglutide. Likewise, this change has made it possible to classify other specific and rare causes of hepatic steatosis, such as hepatotoxicity, immunogenic diseases, hepatitis C or celiac disease.

01 Jul 2025·Annals of Hepatology

Updated recommendations for the management of metabolic dysfunction–associated steatotic liver disease (MASLD) by the Latin American working group

Article

Author: Valério, Cynthia ; Pessoa, Mario G ; Acevedo, Mónica ; Hernández, Nelia ; Moreira, Rodrigo Oliveira ; Arab, Juan Pablo ; Arrese, Marco ; Perelli, Javiera ; Diaz, Luis Antonio ; Gadano, Adrian ; Castro-Narro, Graciela ; Carreño, Javiera ; Brahm, Javier ; Samith, Bárbara ; Dirchwolf, Melisa ; Idalsoaga, Francisco ; Oliveira, Claudia P ; Vega, Javier

Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the leading causes of chronic liver disease globally. Based on the 2023 definition, MASLD is characterized by the presence of metabolic dysfunction and limited alcohol consumption (<140 grams/week for women, <210 grams/week for men). Given the significant burden of MASLD in Latin America, this guidance was developed by the Latin American Association for the Study of the Liver (ALEH) Working Group to address key aspects of its clinical assessment and therapeutic strategies. In Latin America, ultrasonography is recommended as the initial screening tool for hepatic steatosis due to its accessibility, while Fibrosis-4 (FIB-4) is preferred for fibrosis risk stratification, with further evaluation using more specific techniques (i.e., vibration-controlled transient elastography or Enhanced Liver Fibrosis [ELF] test). A Mediterranean diet is advised for all MASLD patients, with a target of 7-10% weight loss for those with excess weight. Complete alcohol abstinence is recommended for patients with significant fibrosis, and smoking cessation is encouraged regardless of fibrosis stage. Pharmacological options should be tailored based on the presence of steatohepatitis, liver fibrosis, excess weight, and diabetes, including resmetirom, incretin-based therapies, pioglitazone, and sodium-glucose cotransporter-2 inhibitors. Bariatric surgery may be considered for MASLD patients with obesity unresponsive to lifestyle and medical interventions. Hepatocellular carcinoma screening is advised for all cirrhotic patients, with consideration given to those with advanced fibrosis based on individual risk. Finally, routine cardiovascular risk assessment and proper diabetes prevention and management remain crucial for all patients with MASLD.

297

News (Medical) associated with Resmetirom

20 Jun 2025

·www.globenewswire.com

Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

Positive recommendation based on resmetirom’s favorable profile including positive results from the pivotal Phase 3 MAESTRO-NASH trialEuropean Commission decision expected in August 2025; if approved, resmetirom will be the first medication for people living with MASH in the E.U. CONSHOHOCKEN, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of resmetirom (Rezdiffra) for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis. The European Commission decision is anticipated in August. Bill Sibold, Chief Executive Officer of Madrigal, stated, “Madrigal is singularly focused on leading the fight against MASH globally. Resmetirom was the first medication to achieve fibrosis improvement and MASH resolution in a Phase 3 trial, the first medication to receive FDA-approval for MASH, and today’s positive CHMP opinion represents another historic first for the global MASH community. MASH is the fastest-growing indication for liver transplantation in Europe, and we believe resmetirom has the potential to address the urgent unmet need for a foundational, liver-directed therapy to treat patients with this serious disease.” MASH is a leading cause of liver-related mortality and an increasing burden on healthcare systems globally. Resmetirom is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. The CHMP opinion was based on resmetirom’s favorable profile including the positive results from the pivotal Phase 3 MAESTRO-NASH trial, which achieved both fibrosis reduction and MASH resolution primary endpoints. Jörn M. Schattenberg, M.D., Professor of Medicine and Director of the Department of Medicine at the University Medical Center Homburg and University of the Saarland in Germany, stated, “I’m encouraged by the CHMP’s positive opinion recommending approval of resmetirom. After years of clinical research and growing appreciation of the burden of MASH on patients and health systems across Europe, we are finally on the cusp of having an approved therapy that targets the underlying disease. Importantly, resmetirom is already included in European clinical practice guidelines, which provide a framework for identifying and monitoring patients with noninvasive tests. If approved, I believe the medication has the potential to transform care for my patients with MASH.” The U.S. Food and Drug Administration (FDA) granted accelerated approval in March 2024 for Rezdiffra in conjunction with diet and exercise for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis). Continued approval for this indication may be contingent upon verification and description of clinical benefit in ongoing confirmatory trials. About MASHMetabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), is a serious liver disease that can progress to cirrhosis, liver failure, liver cancer, need for liver transplantation, and premature mortality. MASH is the leading cause of liver transplantation in women and the second leading cause of all liver transplantation in the U.S., and the fastest-growing indication for liver transplantation in Europe. Once patients progress to MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), the risk of adverse liver outcomes increases dramatically: these patients have a 10-17 times higher risk of liver-related mortality as compared to patients without fibrosis. Those who progress to cirrhosis face a 42 times higher risk of liver-related mortality, underscoring the need to treat MASH before complications of cirrhosis develop. MASH is also an independent driver of cardiovascular disease, the leading cause of mortality for patients. As MASH disease awareness improves and disease prevalence increases, the number of diagnosed patients with MASH with moderate to advanced fibrosis or compensated MASH cirrhosis (F2-F4c) is expected to grow. About RezdiffraRezdiffra is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. It is the first approved medication for the treatment of MASH in the U.S. In the pivotal Phase 3 MAESTRO-NASH biopsy trial, Rezdiffra achieved both fibrosis improvement and MASH resolution primary endpoints, and 91% of patients treated with Rezdiffra 100 mg experienced improvement or stabilization of liver stiffness. In the U.S., Rezdiffra is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis). Continued approval for this indication may be contingent upon verification and description of clinical benefit in ongoing confirmatory trials. Rezdiffra is not approved in Europe for the treatment of patients with MASH with moderate to advanced liver fibrosis and not approved in any geography for the treatment of patients with cirrhosis. The ongoing, fully enrolled MAESTRO-NASH OUTCOMES trial is evaluating progression to liver decompensation events in patients with compensated MASH cirrhosis treated with Rezdiffra versus placebo. What is Rezdiffra?Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. It is not known if Rezdiffra is safe and effective in children (under 18 years old).This indication is approved based on improvement of NASH and liver scarring (fibrosis). There are ongoing studies to confirm the clinical benefit of Rezdiffra. Before you take Rezdiffra, tell your healthcare provider about all of your medical conditions, including if you: have any liver problems other than NASH.have gallbladder problems or have been told you have gallbladder problems, including gallstones.are pregnant or plan to become pregnant. It is not known if Rezdiffra will harm your unborn baby.are breastfeeding or plan to breastfeed. It is not known if Rezdiffra passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take Rezdiffra. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Rezdiffra and other medicines may affect each other, causing side effects. Rezdiffra may affect the way other medicines work, and other medicines may affect how Rezdiffra works.Especially tell your healthcare provider if you take medicines that contain gemfibrozil to help lower your triglycerides, or cyclosporine to suppress your immune system, because Rezdiffra is not recommended in patients taking these medicines.Tell your healthcare provider if you are taking medicines such as clopidogrel to thin your blood or statin medicines to help lower your cholesterol.Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine. What are the possible side effects of Rezdiffra?Rezdiffra may cause serious side effects, including: liver injury (hepatotoxicity). Stop taking Rezdiffra and call your healthcare provider right away if you develop the following signs or symptoms of hepatotoxicity: tiredness, nausea, vomiting, fever, rash, your skin or the white part of your eyes turns yellow (jaundice), pain or tenderness in the upper middle or upper right area of your stomach (abdomen).gallbladder problems. Gallbladder problems such as gallstones, inflammation of the gallbladder, or inflammation of the pancreas from gallstones can occur with NASH and may occur if you take Rezdiffra. Call your healthcare provider right away if you develop any signs or symptoms of these conditions including nausea, vomiting, fever, or pain in your stomach area (abdomen) that is severe and will not go away. The pain may be felt going from your abdomen to your back and the pain may happen with or without vomiting. The most common side effects of Rezdiffra include: diarrhea, nausea, itching, stomach (abdominal) pain, vomiting, dizziness, constipation. These are not all the possible side effects of Rezdiffra. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Madrigal at 1-800-905-0324. Please see the full Prescribing Information, including Patient Information, for Rezdiffra. About Madrigal Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by the FDA for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c). For more information, visit www.madrigalpharma.com. Forward-Looking StatementsThis press release includes “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended, including statements related to the expected timing for a decision for marketing authorization by the European Commission and resmetirom’s role as a potential foundational therapy for the treatment of MASH in Europe. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to: the assumptions underlying the forward-looking statements; risks of obtaining and maintaining regulatory approvals, including, but not limited to, potential regulatory delays or rejections; the challenges with the commercial launch of a new product, particularly for a company that did not have commercial experience prior to 2024; our history of operating losses and the possibility that we may never achieve or maintain profitability; risks associated with meeting the objectives of Madrigal’s clinical trials, including, but not limited to Madrigal’s ability to achieve enrollment objectives concerning patient numbers (including an adequate safety database), outcomes objectives and/or timing objectives for Madrigal’s trials; any delays or failures in enrollment, and the occurrence of adverse safety events; risks related to the effects of Rezdiffra’s (resmetirom’s) mechanism of action; market demand for and acceptance of Rezdiffra; the potential inability to raise sufficient capital to fund ongoing operations as currently planned or to obtain financing on acceptable terms; our ability to service indebtedness and otherwise comply with debt covenants; outcomes or trends from competitive trials; future topline data timing or results; our ability to prevent and/or mitigate cyber-attacks; the uncertainties inherent in clinical testing; uncertainties concerning analyses or assessments outside of a controlled clinical trial; and changes in laws and regulations applicable to our business and our ability to comply with such laws and regulations. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Madrigal undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Please refer to Madrigal’s submissions filed with the U.S. Securities and Exchange Commission(“SEC”), for more detailed information regarding these risks and uncertainties and other factors that may cause actual results to differ materially from those expressed or implied. Madrigal specifically discusses these risks and uncertainties in greater detail in the sections appearing in Part I, Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 26, 2025, and as updated from time to time by Madrigal’s other filings with the SEC. Investor ContactTina Ventura, IR@madrigalpharma.com Media ContactChristopher Frates, media@madrigalpharma.com

Clinical ResultPhase 3Drug ApprovalAccelerated Approval

20 Jun 2025

·firstwordpharma.com

Madrigal's Rezdiffra nears EU approval for MASH after positive panel review

A European Medicines Agency (EMA) committee recommended conditional approval of Madrigal Pharmaceuticals' Rezdiffra (resmetirom) for adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis, in conjunction with diet and exercise. Clearance of the THR-β selective agonist, expected in August, would mark the first authorisation for a drug in this indication in the EU.Approved in the US last year as the first treatment in the country for MASH, Rezdiffra has gotten off to a strong start, generating sales of $137.3 million in the first three months of 2025. A recent FirstWord poll found that six-in-10 physicians in the US expect their use of the drug to increase over the next 12 months.The decision announced Friday from the EMA's Committee for Medicinal Products for Human Use (CHMP) was based on interim findings from the pivotal MAESTRO-NASH study. Results showed that after a year of treatment in patients with stage F2 and F3 liver fibrosis, 30% of those given a 100-mg dose of Rezdiffra and 26% of those on an 80-mg dose achieved MASH resolution with no worsening of fibrosis, compared to 10% in the placebo group. The trial also demonstrated that 29% of patients who received Rezdiffra 100 mg and 27% of those on the lower dose experienced an improvement in liver scarring and no worsening of MASH, versus 17% for the placebo group.The EMA noted that results from the pivotal study, which is still under way, and those from another ongoing supporting trial are required to provide further data regarding the efficacy of Rezdiffra.

Clinical ResultDrug Approval

15 May 2025

·pmlive.com

Madrigal’s liver disease drug Rezdiffra shows promise in compensated MASH cirrhosis

Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) has demonstrated sustained efficacy in a late-stage trial of patients with liver disease. The company presented positive two-year results from the open-label compensated metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis arm of its phase 3 MAESTRO-NAFLD-1 trial at this year’s European Association for the Study of the Liver Congress. An estimated 1.5 million people in the US have been diagnosed with MASH, formerly known as nonalcoholic steatohepatitis, which occurs when too much fat builds up in the liver. The disease can progress to cirrhosis, liver failure, liver cancer and is the leading cause of liver transplantation among women. Taken orally once daily, Rezdiffra is a liver-directed thyroid-hormone receptor-beta (THR-β) agonist designed to target key underlying causes of MASH. The drug has already been granted accelerated in the US to treat non-cirrhotic cases, but is not currently approved in any market for MASH patients with cirrhosis. New results from MAESTRO-NAFLD-1 showed that Rezdiffra-treated compensated MASH cirrhosis patients achieved significant improvements from baseline in liver stiffness, liver fat, fibrosis biomarkers, liver volume and risk scores for clinically significant portal hypertension (CSPH), a major consequence of cirrhosis that is linked to severe complications. Among patients with CSPH at baseline, 65% moved into lower risk categories by year two, while 57% of those with probable CSPH at baseline moved into the no or low CSPH category. Safety data was also found to be consistent with previous studies, and Rezdiffra was well-tolerated. Madrigal’s chief medical officer, David Soergel, said: “Lower THR-β activity in the liver is predictive of hepatic decompensation in patients with MASH, so there is a strong mechanistic rationale supporting the potential of Rezdiffra, a THR-β agonist, to improve outcomes in patients with compensated MASH cirrhosis. “This two-year open-label data from MAESTRO-NAFLD-1 adds important clinical evidence that supports our confidence in the ongoing, fully enrolled phase 3 outcomes trial of Rezdiffra in compensated MASH cirrhosis.” It is hoped that positive results from the MAESTRO-NASH OUTCOMES study would support the full approval of Rezdiffra for non-cirrhotic MASH and expand the indication to those with cirrhosis.

Phase 3Clinical ResultAccelerated Approval

100 Deals associated with Resmetirom

External Link

KEGG	Wiki	ATC	Drug Bank
D11602	-	-	DB12914

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Fibrosis, Liver	United States	Madrigal Pharmaceuticals, Inc.	14 Mar 2024
Nonalcoholic Steatohepatitis	United States	Madrigal Pharmaceuticals, Inc.	14 Mar 2024

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Liver Cirrhosis	Phase 3	United States	Madrigal Pharmaceuticals, Inc.	26 Aug 2022
Liver Cirrhosis	Phase 3	Puerto Rico	Madrigal Pharmaceuticals, Inc.	26 Aug 2022
Fibrosis	Phase 3	Australia	Madrigal Pharmaceuticals, Inc.	28 Mar 2019
Fibrosis	Phase 3	Austria	Madrigal Pharmaceuticals, Inc.	28 Mar 2019
Fibrosis	Phase 3	Belgium	Madrigal Pharmaceuticals, Inc.	28 Mar 2019
Fibrosis	Phase 3	Canada	Madrigal Pharmaceuticals, Inc.	28 Mar 2019
Fibrosis	Phase 3	France	Madrigal Pharmaceuticals, Inc.	28 Mar 2019
Fibrosis	Phase 3	Germany	Madrigal Pharmaceuticals, Inc.	28 Mar 2019
Fibrosis	Phase 3	Hungary	Madrigal Pharmaceuticals, Inc.	28 Mar 2019
Fibrosis	Phase 3	Israel	Madrigal Pharmaceuticals, Inc.	28 Mar 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04197479 (MAESTRO-NAFLD-1, Company_Website) Manual	Phase 3	Nonalcoholic Steatohepatitis	113	Rezdiffra	ptiukiwesn(dbuwalivhj) = jsiamjbnme zwlayixqat (kfjlraskki ) View more	Positive	10 May 2025
NCT03900429 (MAESTRO-NASH, UEGW2024)	Phase 3	Nonalcoholic Steatohepatitis	966	Resmetirom 80 mg	odqfycnygd(hsnleygjfu) = pejcrtnfbo vhpipaulzo (rrckcqcoxm ) View more	Positive	13 Oct 2024
				Resmetirom 100 mg	odqfycnygd(hsnleygjfu) = mekhznntbg vhpipaulzo (rrckcqcoxm ) View more
UEGW2024	Not Applicable	Nonalcoholic Steatohepatitis	-	Resmetirom 80 mg	cbmeqrhvrc(yyobdljofd) = qtecapudxx ftwlnfhkgy (axsuhqykwe, 4.61)	-	13 Oct 2024
				Resmetirom 100 mg	cbmeqrhvrc(yyobdljofd) = ekxeadxvay ftwlnfhkgy (axsuhqykwe, 4.76)
NCT03900429 (MAESTRO-NASH, UEGW2024)	Phase 3	Nonalcoholic Steatohepatitis Carbohydrate Deficient Transferrin (CDT) \| PEth test	966	Resmetirom 80 mg	aeqqyynguw(hwkvdporwj) = hjokpcoqje eudeqarhil (ybhpchxzsg ) View more	Positive	13 Oct 2024
				Resmetirom 100 mg	aeqqyynguw(hwkvdporwj) = nxfvmwtbxe eudeqarhil (ybhpchxzsg ) View more
NCT03900429 (MAESTRO-NASH, UEGW2024)	Phase 3	FibroScan CAP \| Fibroscan VCTE \| alanine aminotransferase (ALT)	966	Resmetirom 80 mg	hzxwcsrhhd(essakuxezs) = ylzzhnnvhd kgwrclrkyi (wckelpqefo, 6.8)	Positive	13 Oct 2024
				Resmetirom 100 mg	hzxwcsrhhd(essakuxezs) = opajzfsspg kgwrclrkyi (wckelpqefo, 7.1)
NCT03900429 (FDA) Manual	Phase 3	Fibrosis, Liver \| Nonalcoholic Steatohepatitis	-	placebo	auanxbyjjk(demtdkdznk) = egnhfkzeqp biadhxghqo (nwjtvgnezr ) View more	Superior	14 Mar 2024
				REZDIFFRA (80 mg once daily)	auanxbyjjk(demtdkdznk) = phfvlcfioe biadhxghqo (nwjtvgnezr ) View more
NCT03900429 (MAESTRO-NASH, Pubmed) Manual	Phase 3	Nonalcoholic Steatohepatitis	966	Resmetirom 80 mg	tjkmrufvmd(blqibwufuj) = tpuukgjioz zofszjlxdc (ugrwgvzgra ) View more	Positive	08 Feb 2024
				Resmetirom 100 mg	tjkmrufvmd(blqibwufuj) = pkqbligebu zofszjlxdc (ugrwgvzgra ) View more
NCT03900429 (MAESTRO-NASH, GlobeNewswire) Manual	Phase 3	Nonalcoholic Steatohepatitis	-	Resmetirom 100 mg	cmxwvibita(lqzsjlyyps) = uszhbjlgvf yggfoujvaq (svrnzxzsed ) View more	Positive	10 Nov 2023
NCT04197479 (MAESTRO-NAFLD1, Literature \| Pubmed \| Nat Med) Manual	Phase 3	Metabolic dysfunction-associated steatotic liver disease	972	resmetirom 100 mg	hdurdfdqhs(qhiowsbwrb) = thgkaxoatq upmrrffvza (crwjxmjdsg )	Positive	16 Oct 2023
				resmetirom 80 mg	hdurdfdqhs(qhiowsbwrb) = owmfjnscyd upmrrffvza (crwjxmjdsg )
NCT03900429 (MAESTRO-NASH, UEGW2023)	Phase 3	Nonalcoholic Steatohepatitis liver stiffness \| hepatic fat \| nonalcoholic fatty liver disease activity score (NAS)	966	Resmetirom 80 mg	hfqrczpjvy(kerecmhovb) = mdidoocnxq uiukfyxhzb (wuuygayhvc ) View more	Positive	15 Oct 2023
				Resmetirom 100 mg	hfqrczpjvy(kerecmhovb) = zowxwltvkd uiukfyxhzb (wuuygayhvc ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis